
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics is a fundamentally strong company that is set for future growth due to its partnerships and new developments in its product line. With a strong brand reputation and projected earnings growth, HAE's stock has a Buy rating and potential for sustained success in the competitive medical technology industry. The company's financials and key data metrics support this positive outlook, with a strong revenue guidance and expected benefit from new products and acquisitions.
Bears say
Haemonetics is a medical technology company that operates in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. While the company has a strong presence in the growing plasma collection market and is experiencing growth in its core Plasma division, their Blood Center business is being rationalized to shed less profitable revenue. The company also faces stiff competition in the MedSurg segment and potential challenges in integrating its recent acquisitions, which may impact their overall financial performance in the future.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares